Corporate Performance
Corporate Performance Articles
Counting out a tobacco company has never proved to be a good bet over the long term. Will this time be different?
Published:
A class-action lawsuit was filed against Lyft by a former driver in Washington, D.C., contending that the company is contributing to the spread of COVID-19 by its failure to provide paid time off for...
Published:
Roku stands to benefit as consumers spend more on streaming services and advertisers look likely to follow suit.
Published:
Boeing has faced a rough year between the COVID-19 pandemic and the grounding of its 737 Max. Has its stock bottomed -- and can it recover from here?
Published:
A number of U.S. cities have been hit with protests, some of which have turned violent. Retail locations in these places face damage.
Published:
With most Disney businesses drastically affected by the COVID-19 pandemic, the questions of how and when various units will return to operation are vital for the company, its bottom line and its...
Published:
If analysts are right, Nvidia stock is still a buy, even though shares are trading well above the consensus price target.
Published:
Last Updated:
The iPhone gets all the attention, but investors shouldn’t forget the other products produced by Apple.
Published:
Amazon is certainly making Jeff Bezos richer and richer, but is it a force for good for the rest of us?
Published:
No one outside AT&T is likely to call the company's May 27 launch of HBO Max a rousing success. Does HBO have to think differently about how to add new subscribers long term?
Published:
The pandemic has caused supply and demand problems for Ford and damaged consumer confidence.
Published:
Consumer habits have changed and Shopify is well positioned to benefit however the pandemic plays out.
Published:
Zoom Video Communications has a market capitalization of above $50 billion. The General Motors market cap is near $37 billion. The figures seem absurd.
Published:
Ford will likely have the summertime blues when it comes to reaching its sales goals. How bad those blues will be depends on the pandemic, unemployment numbers, and consumer sentiment.
Published:
While Amarin supports research into Vascepa's possible use in treating COVID-19, the financial benefits promise to be greater if Vascepa's patents are upheld. Of course, Wall Street is bound to lift...
Published: